Mirum Pharmaceuticals (MIRM) announced that the first participant has been enrolled in the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome. The study will evaluate the safety, tolerability, and potential clinical benefit of MRM-3379 in male participants with a confirmed genetic diagnosis of Fragile X syndrome. Top-line data from Phase 2 is expected in 2027.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals: Strategic Positioning and Strong Defense Justify Buy Rating
- Mirum Pharmaceuticals Faces Patent Challenge from Sandoz
- Mirum Pharmaceuticals Reports Robust Q3 Growth and Milestones
- Mirum Pharmaceuticals price target raised to $95 from $85 at Cantor Fitzgerald
- Mirum Pharmaceuticals price target raised to $81 from $80 at H.C. Wainwright